← All trials
NCT01836328
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2011
- Primary completion
- Jun 1, 2015
- Completion date
- Jun 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 44
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- L'Hospitalet de LlobregatLead sponsor
- L'Hospitalet de LlobregatReponsible party - principal investigator
- Universidad Autonoma de MadridCollaborator
- Hospital Universitario Arnau de Vilanova de LleidaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.